<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04906980</url>
  </required_header>
  <id_info>
    <org_study_id>CR108919</org_study_id>
    <secondary_id>64281802DNG2003</secondary_id>
    <nct_id>NCT04906980</nct_id>
  </id_info>
  <brief_title>A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever</brief_title>
  <official_title>A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety and Tolerability, and Pharmacokinetics of JNJ-64281802 in Participants With Confirmed Dengue Fever</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the antiviral activity of JNJ-64281802 versus&#xD;
      placebo in terms of reduction of dengue virus (DENV) ribonucleic acid (RNA) in primary DENV&#xD;
      infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 31, 2021</start_date>
  <completion_date type="Anticipated">May 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 19, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Log10-transformed Dengue Virus (DENV) Ribonucleic Acid (RNA) Viral Load (VL) Curve from Baseline Until Day 5 (AUCD1-D5 [log10VL])</measure>
    <time_frame>Baseline, up to Day 5</time_frame>
    <description>Area under the log10-transformed DENV RNA VL curve from baseline until Day 5 will be reported.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Electrocardiogram (ECGs)</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Number of participants with clinically significant abnormalities in ECGs will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Physical Examination</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Number of participants with clinically significant abnormalities in physical examination (head/neck/thyroid, eyes/ears/nose/throat, respiratory, cardiovascular, lymph nodes, abdomen, skin, musculoskeletal, and neurological) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Vital Signs</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Number of participants with clinically significant abnormalities in vital signs (temperature, pulse/heart rate, respiratory rate, peripheral capillary oxygen saturation [spO2], input-output [I/O] ratio and blood pressure) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Abnormalities in Laboratory Parameters</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Number of participants with clinically significant abnormalities in laboratory parameters (serum chemistry, hematology, and coagulation) will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Detectable DENV RNA in Primary DENV Infection</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Occurrence of detectable DENV RNA in primary DENV infection will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Undetectable DENV RNA in Primary DENV Infection</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Time to undetectable DENV RNA in primary DENV infection will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve During one Dosing Interval (AUCtau) of JNJ-64281802</measure>
    <time_frame>Predose (day 1, 2, 3, 4 and 5), post dose up to Day 28</time_frame>
    <description>AUCtau is defined as area under the concentration curve during one dosing interval of JNJ-64281802.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Analyte Concentration (Cmax) of JNJ-64281802</measure>
    <time_frame>Predose up to 5 days; post dose up to Day 28</time_frame>
    <description>Cmax is defined as the maximum observed analyte concentration of JNJ-64281802.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Observed Analyte Concentration (Ctrough) of JNJ-64281802</measure>
    <time_frame>Predose up to 5 days; post dose up to Day 28</time_frame>
    <description>Ctrough is defined as observed analyte concentration just prior to the beginning or at the end of a dosing interval of JNJ-64281802.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Dengue</condition>
  <arm_group>
    <arm_group_label>JNJ-64281802</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participant will receive 2 initial loading doses of JNJ-64281802, 800 milligram (mg) every 8 hours (q8h) followed by 4 doses of 400 mg q8h then 2 single doses of 400 mg on Day 4 and Day 5.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo orally once daily from Day 1 to Day 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JNJ-64281802</intervention_name>
    <description>JNJ-64281802 will be administered orally.</description>
    <arm_group_label>JNJ-64281802</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo (PEG400) will be administered orally.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant with healthcare clinic (HCC) referral note/documentation indicating&#xD;
             non-structural protein 1 (NS1) positive for dengue virus (DENV) or Participant who&#xD;
             tests NS1 positive at the site after having undergone the NS1 rapid test for DENV&#xD;
&#xD;
          -  Participant reported a fever with an onset within the last 48 hours&#xD;
&#xD;
          -  A woman of childbearing potential must have a negative serum pregnancy test at&#xD;
             screening&#xD;
&#xD;
          -  A woman must be: a. not of childbearing potential, b. of childbearing potential and&#xD;
             practicing a highly effective, preferably user-independent method of contraception&#xD;
             (failure rate of less than [&lt;] 1% per year when used consistently and correctly) and&#xD;
             agrees to remain on a highly effective method while receiving study intervention and&#xD;
             until at least 90 days after last dose- the end of relevant systemic exposure&#xD;
&#xD;
          -  A male participant must agree not to donate sperm for the purpose of reproduction&#xD;
             during the study and for a minimum of 90 days after receiving the last dose of study&#xD;
             intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant with any clinical signs and symptoms for severe dengue according to the&#xD;
             world health organization (WHO) criteria (such as severe plasma leakage leading to&#xD;
             dengue shock syndrome [DSS], fluid accumulation with respiratory distress, severe&#xD;
             bleeding, sever organ involvement)&#xD;
&#xD;
          -  Use of any cytochrome 3A4 (CYP3A4) inhibitors (example, clarithromycin, itraconazole),&#xD;
             CYP3A4 inducers (example, phenytoin, rifampin), or substrates for CYP3A4 with a narrow&#xD;
             therapeutic range (example, alfentanil, cyclosporin), CYP2C8 (example, repaglinide),&#xD;
             CYP2C9 (example, warfarin, tolbutamide), CYP2C19 (example, S-mephenytoin, omeprazole)&#xD;
             or breast cancer resistance protein (BCRP) (example, pravastatin and folic acid)&#xD;
             within 14 days before first dose of study drug&#xD;
&#xD;
          -  History of malignancy within 5 years before screening (exceptions are squamous and&#xD;
             basal cell carcinomas of the skin and carcinoma in situ of the cervix, or malignancy,&#xD;
             which is considered cured with minimal risk of recurrence)&#xD;
&#xD;
          -  Had major surgery, (example, requiring general anesthesia) within 4 weeks before&#xD;
             screening, or will not have fully recovered from surgery, or has surgery planned&#xD;
             during the time the participant is expected to participate in the study&#xD;
&#xD;
          -  Known or suspected congenital or acquired immunodeficiency; or receipt of&#xD;
             immunomodulation therapy such as anti-cancer chemotherapy or radiation therapy; or&#xD;
             long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2&#xD;
             consecutive weeks within the past 3 months)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Contact</last_name>
    <phone>844-434-4210</phone>
    <email>JNJ.CT@sylogent.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108919</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical- trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu</ipd_description>
    <ipd_url>https://www.janssen.com/clinical-trials/transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

